Epidemiology of Acute Otitis Media Changed From 2006-2016

Share this content:
Epidemiology of Acute Otitis Media Changed From 2006-2016
Epidemiology of Acute Otitis Media Changed From 2006-2016

MONDAY, Aug. 7, 2017 (HealthDay News) -- Since the introduction of pneumococcal vaccines, the epidemiology of acute otitis media (AOM) has changed considerably, but risk factors have not, according to a study published online Aug. 7 in Pediatrics.

Ravinder Kaur, Ph.D., from the Rochester General Hospital Research Institute in New York, and colleagues examined the epidemiology of AOM in a cohort of 615 children, prospectively managed from 6 to 36 months of life during a 10-year time frame (June 2006 to June 2016). AOM diagnoses were confirmed by tympanocentesis and bacterial culture of middle ear fluid.

The researchers found that male sex, non-Hispanic white race, family history of recurrent AOM, day care attendance, and early occurrence of AOM were associated with significantly increased risk of AOM. Risk factors for stringently defined proneness to otitis, in which children had three or more episodes of AOM in a six-month period or four episodes within one year, included male sex, day care attendance, and family history of AOM; breastfeeding in the first six months was a protective factor. Children who were prone to stringently defined otitis were also likely to experience their first episode of AOM at an earlier age. During the past decade there was a dynamic change in the proportion of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing AOM.

"We conclude that the epidemiology but not the risk factors for AOM have undergone substantial changes since the introduction of pneumococcal conjugate vaccines," the authors write.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths